U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Hyperlysinuria

MedGen UID:
867368
Concept ID:
C4021733
Finding
Synonyms: High urine lysine levels; Lysinuria
 
HPO: HP:0003297

Definition

An increased concentration of lysine in the urine. [from HPO]

Conditions with this feature

Cystinuria
MedGen UID:
8226
Concept ID:
C0010691
Disease or Syndrome
Cystinuria is an autosomal disorder characterized by impaired epithelial cell transport of cystine and dibasic amino acids (lysine, ornithine, and arginine) in the proximal renal tubule and gastrointestinal tract. The impaired renal reabsorption of cystine and its low solubility causes the formation of calculi in the urinary tract, resulting in obstructive uropathy, pyelonephritis, and, rarely, renal failure (summary by Barbosa et al., 2012).
Hyperlysinemia
MedGen UID:
82816
Concept ID:
C0268553
Disease or Syndrome
Hyperlysinemia type I is an autosomal recessive metabolic condition with variable clinical features. Some patients who present in infancy with nonspecific seizures, hypotonia, or mildly delayed psychomotor development have been found to have increased serum lysine and pipecolic acid on laboratory analysis. However, about 50% of probands are reported to be asymptomatic, and hyperlysinemia is generally considered to be a benign metabolic variant (summary by Tondo et al., 2013; Houten et al., 2013). The AASS gene encodes a bifunctional enzyme: lysine alpha-ketoglutarate reductase and saccharopine dehydrogenase. In hyperlysinemia type I, both enzymatic functions of AASS are defective; in hyperlysinemia type II, also known as saccharopinuria (268700), some of the first enzymatic function is retained (Cox, 1985; Cox et al., 1986).
Hyperlysinuria with hyperammonemia
MedGen UID:
120650
Concept ID:
C0268555
Disease or Syndrome
Saccharopinuria
MedGen UID:
75693
Concept ID:
C0268556
Disease or Syndrome
Saccharopinuria, also known as hyperlysinemia type II, is an autosomal recessive metabolic condition with few, if any, clinical manifestations. Hyperlysinemia type II and hyperlysinemia type I (238700) both result from deficiency of the bifunctional enzyme AASS (605113) on chromosome 7q31. The AASS gene encodes lysine alpha-ketoglutarate reductase and saccharopine dehydrogenase, which catalyze, respectively, the sequential conversion of lysine to saccharopine and saccharopine to alpha-aminoadipic semialdehyde and glutamate (summary by Tondo et al., 2013). In hyperlysinemia type I, both enzymatic functions of AASS are defective and patients have increased serum lysine and possibly increased saccharopine; in hyperlysinemia type II, most of the first enzymatic function is retained, and patients tend to have isolated saccharopine increase (Cox, 1985; Cox et al., 1986).
Lysinuric protein intolerance
MedGen UID:
75704
Concept ID:
C0268647
Disease or Syndrome
Lysinuric protein intolerance (LPI) typically presents after an infant is weaned from breast milk or formula; variable findings include recurrent vomiting and episodes of diarrhea, episodes of stupor and coma after a protein-rich meal, poor feeding, aversion to protein-rich food, failure to thrive, hepatosplenomegaly, and muscular hypotonia. Over time, findings include: poor growth, osteoporosis, involvement of the lungs (progressive interstitial changes, pulmonary alveolar proteinosis) and of the kidneys (progressive glomerular and proximal tubular disease), hematologic abnormalities (normochromic or hypochromic anemia, leukopenia, thrombocytopenia, erythroblastophagocytosis in the bone marrow aspirate), and a clinical presentation resembling the hemophagocytic lymphohistiocytosis/macrophagic activation syndrome. Hypercholesterolemia, hypertriglyceridemia, and acute pancreatitis can also be seen.
Lysine malabsorption syndrome
MedGen UID:
167097
Concept ID:
C0796023
Disease or Syndrome
Lysine malabsorption with severe malnourishment, extreme flaccidity, and psychomotor retardation.
Seizures-intellectual disability due to hydroxylysinuria syndrome
MedGen UID:
343450
Concept ID:
C1855986
Finding
The presence of an elevated amount of 5-hydroxylysine in the urine. This compound is a hydroxylated derivative of the amino acid lysine that is present in certain collagens.
Progressive encephalopathy with leukodystrophy due to DECR deficiency
MedGen UID:
346552
Concept ID:
C1857252
Disease or Syndrome
2,4-Dienoyl-CoA reductase deficiency (DECRD) is a rare autosomal recessive inborn error of metabolism resulting in mitochondrial dysfunction due to impaired production of NADPH, which is an essential cofactor for several mitochondrial enzymes. Affected individuals have a variable phenotype: some may have severe neurologic symptoms and metabolic dysfunction beginning in early infancy, whereas others may present with more subtle features, such as childhood-onset optic atrophy or intermittent muscle weakness. The variable severity is putatively dependent on the effect of the mutation on the NADK2 enzyme. Biochemical analysis typically shows hyperlysinemia, due to defective activity of the mitochondrial NADP(H)-dependent enzyme AASS (605113), which is usually a benign finding. More severe cases have increased C10:2-carnitine levels, due to defective activity of the enzyme DECR (DECR1; 222745) (summary by Houten et al., 2014 and Pomerantz et al., 2018).
Diaminopentanuria
MedGen UID:
347412
Concept ID:
C1857285
Disease or Syndrome
Hyperdibasic aminoaciduria type 1
MedGen UID:
435997
Concept ID:
C2673736
Disease or Syndrome
Hyperdibasic aminoaciduria, type 1 is characterized by increased renal clearance of lysine, ornithine and arginine, in the presence of normal concentrations of cystine. Heterozygous individuals are asymptomatic but homozygotes display intellectual deficit. To date, 25 heterozygotes and one homozygote have been reported.

Recent clinical studies

Etiology

Cederbaum SD, Shaw KN, Dancis J, Hutzler J, Blaskovics JC
J Pediatr 1979 Aug;95(2):234-8. doi: 10.1016/s0022-3476(79)80657-5. PMID: 571908

Diagnosis

Lehnert W, Sperl W, Suormala T, Baumgartner ER
Eur J Pediatr 1994;153(7 Suppl 1):S68-80. doi: 10.1007/BF02138781. PMID: 7957390
Cederbaum SD, Shaw KN, Dancis J, Hutzler J, Blaskovics JC
J Pediatr 1979 Aug;95(2):234-8. doi: 10.1016/s0022-3476(79)80657-5. PMID: 571908
Yatziv S, Statter M, Merin S
J Lab Clin Med 1979 May;93(5):749-57. PMID: 429873

Therapy

Brown JH, Fabre LF Jr, Farrell GL, Adams ED
Am J Dis Child 1972 Jul;124(1):127-32. doi: 10.1001/archpedi.1972.02110130129021. PMID: 5033744

Prognosis

Lehnert W, Sperl W, Suormala T, Baumgartner ER
Eur J Pediatr 1994;153(7 Suppl 1):S68-80. doi: 10.1007/BF02138781. PMID: 7957390

Clinical prediction guides

Lehnert W, Sperl W, Suormala T, Baumgartner ER
Eur J Pediatr 1994;153(7 Suppl 1):S68-80. doi: 10.1007/BF02138781. PMID: 7957390
Atanasova E
Acta Med Iugosl 1990;44(2):163-75. PMID: 2112825

Supplemental Content

Table of contents

    Clinical resources

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...